Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 869

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 869
---
 Kineta assigned all rights to its sole and joint inventions and patents related to the CD27 program back to GigaGen and transferred all related data and regulatory filings. Both parties
released each other from any claims related to the CD27 Agreement and agreed to maintain confidentiality and cooperate in perfecting the transfer of intellectual property.

F-131

Annex A

AGREEMENT AND PLAN OF MERGER

among

TUHURA BIOSCIENCES, INC.,

HURA MERGER SUB I, INC.

HURA MERGER SUB II, LLC

KINETA, INC.

and

CRAIG PHILIPS,

solely in his capacity as STOCKHOLDERS REPRESENTATIVE

Dated as of December 11, 2024

TABLE OF CONTENTS

|                                                                         |     |                                                                          |     | Page |      |
| ARTICLE I THE MERGERS                                                   |     |                                                                          |     |      | A-2  |
| Section 1.1                                                             |     | The Mergers                                                              |     |      | A-2  |
| Section 1.2                                                             |     | Closing                                                                  |     |      | A-2  |
| Section 1.3                                                             |     | Effective Time                                                           |     |      | A-2  |
| Section 1.4                                                             |     | Effects of the Mergers                                                   |     |      | A-3  |
| Section 1.5                                                             |     | Certificate of Incorporation; Bylaws                                     |     |      | A-3  |
| Section 1.6                                                             |     | Directors and Officers of the Surviving Entity and the Surviving Company |     |      | A-3  |
| ARTICLE II EFFECT ON THE CAPITAL STOCK OF THE CONSTITUENT CORPORATIONS; 
 EXCHANGE OF CERTIFICATES                                                |     |                                                                          |     |      | A-3  |
| Section 2.1                                                             |     | Conversion of Capital Stock                                              |     |      | A-3  |
| Section 2.2                                                             |     | Agreements Relating to Company Stock Options and Company Warrants        |     |      | A-4  |
| Section 2.3                                                             |     | Disposed Asset Payment Right from Permitted Asset Dispositions           |     |      | A-5  |
| Section 2.4                                                             |     | Purchase Price Adjustment                                                |     |      | A-5  |
| Section 2.5                                                             |     |